Intravenous Acetaminophen for Renal Colic in the Emergency Department: Where Do We Stand?

被引:11
|
作者
Sin, Billy [1 ,2 ]
Koop, Kimberly [3 ]
Liu, Michelle [3 ]
Yeh, Jun-Yen [4 ]
Thandi, Pardeep [5 ]
机构
[1] LIU Pharm, Arnold & Marie Schwartz Coll Pharm, Div Pharm Practice, Brooklyn, NY USA
[2] Brooklyn Hosp Ctr, Div Pharmacotherapy, Dept Pharm, Brooklyn, NY USA
[3] LIU Pharm, Arnold & Marie Schwartz Coll Pharm, Brooklyn, NY USA
[4] LIU Pharm, Arnold & Marie Schwartz Coll Pharm, Drug Regulatory Affairs MS Program, Brooklyn, NY USA
[5] Brooklyn Hosp Ctr, Dept Emergency Med, Brooklyn, NY USA
关键词
intravenous acetaminophen; intravenous paracetamol; renal colic; analgesics; pain; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; PARACETAMOL; IMPACT; PAIN; REQUIREMENTS; ANALGESIA; MORPHINE; OPIOIDS; BYPASS;
D O I
10.1097/MJT.0000000000000526
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background:The efficacy, safety, opioid-sparing effects, and cost-benefit analyses of intravenous (IV) acetaminophen (APAP) in treating renal colic remain controversial.Study Question:To evaluate the safety, efficacy, opioid-sparing effects, and cost-benefits of IV APAP in patients who present with renal colic in the emergency department (ED).Data Sources:We systematically searched PubMed (January 1970 to April 2016).Study Design:Randomized controlled trials which evaluated IV APAP for renal colic in the ED were eligible. The clinical outcomes measured were change in pain scores from baseline, incidence of adverse events, use of rescue analgesia, and cost-benefits. Forest plots were constructed using the Mantel-Haenszel method in a random effect model to changes in pain scores from the baseline to designated intervals.Results:The analysis suggested a difference in pain reduction favoring IV APAP over morphine. IV APAP had a significant effect in pain reduction than IV morphine (difference in mean pain score reduction = 7.5 in a 100-point visual analog scale (VAS); 95% confidence interval [CI], 1.99-13.00; P = 0.008). There was mild-to-moderate study heterogeneity (I-2 = 42%). No difference was observed when IV APAP was compared with intramuscular piroxicam for pain reduction (difference in mean pain score reduction = 0.17 in a VAS reduction 50% VAS; 95% CI, -0.22 to 0.57) and to intramuscular diclofenac (difference in mean pain score reduction = 0.00 in a numeric rating scale reduction 50%; 95% CI, -0.12 to 0.12). The analysis for nonsteroidal anti-inflammatory drugs versus IV APAP revealed no difference (difference in mean pain score reduction = 0.01 in a 100-point VAS; 95% CI, -0.10 to 0.13; P = 0.80).Conclusions:In this meta-analysis, we found that data on the efficacy, safety, opioid-sparing effects, and cost-benefit analyses of IV APAP for renal colic were weak. Based on the available data, IV APAP should not be considered as an alternative to opioids or nonsteroidal anti-inflammatory drugs for the primary management of renal colic in the ED.
引用
收藏
页码:E12 / E19
页数:8
相关论文
共 50 条
  • [21] Renal Denervation for Resistant Hypertension: Where Do We Stand?
    Bo Liang
    Yu-Xiu Zhao
    Ning Gu
    [J]. Current Hypertension Reports, 2020, 22
  • [22] Opportunities and Limitations of Renal Denervation: Where Do We Stand?
    Rodriguez, Beatriz Castillo
    Secemsky, Eric A.
    Swaminathan, Rajesh V.
    Feldman, Dmitriy N.
    Schlaich, Markus
    Battaglia, Yuri
    Filippone, Edward J.
    Krittanawong, Chayakrit
    [J]. AMERICAN JOURNAL OF MEDICINE, 2024, 137 (08): : 712 - 718
  • [23] Where do we stand?
    Thompson, ID
    [J]. FORESTRY CHRONICLE, 2003, 79 (03): : 381 - 382
  • [24] Where do we stand?
    不详
    [J]. INTERNATIONAL JOURNAL OF PRODUCTIVITY AND PERFORMANCE MANAGEMENT, 2010, 59 (03) : 79 - 86
  • [25] Where do we stand?
    Catt, Graham
    [J]. AUSTRALIAN VETERINARY JOURNAL, 2008, 86 (07) : N8 - N8
  • [26] WHERE DO WE STAND
    MCMILLAN, B
    [J]. IRE TRANSACTIONS ON INFORMATION THEORY, 1957, 3 (03): : 173 - 174
  • [27] WHERE DO WE STAND?
    Stolper, Gustav
    [J]. HARVARD BUSINESS REVIEW, 1931, 9 (03) : 289 - 298
  • [28] WHERE DO WE STAND
    不详
    [J]. MILITARY MEDICINE, 1961, 126 (01) : 66 - &
  • [29] Molecular Analysis of Renal Allograft Biopsies: Where Do We Stand and Where Are We Going?
    Snijders, Malou L. H.
    Varol, Hilal
    van der Zwan, Marieke
    Becker, Jan U.
    Hesselink, Dennis A.
    Baan, Carla C.
    von der Thusen, Jan H.
    Clahsen-van Groningen, Marian C.
    [J]. TRANSPLANTATION, 2020, 104 (12) : 2478 - 2486
  • [30] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    [J]. TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264